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Clinical Leadership Theme 
 
This project focuses on the Clinical Nurse Leader (CNL) elements: Systems Analyst/Risk 
Anticipator, Outcomes Manager, and Educator. As a system analyst and risk anticipator, the 
CNL reviews systems to improve the quality of patient care delivery and anticipates and 
mitigates risks to patient safety. As an Outcomes Manager, the CNL synthesizes data, 
information and knowledge to evaluate and achieve optimal client outcomes. As an Educator, the 
CNL uses teaching strategies and current information and technologies to teach healthcare 
professionals (American Association of Colleges of Nursing, 2007). The specific aim statement 
is to reduce the number of fatal opioid overdoses in our county by 75 percent within 12 months 
by providing education for local healthcare providers on intranasal naloxone administration for 
opioid users or their family, friends, peers, or members of their social network. 
Statement of the Problem 
The opioid epidemic has spread worldwide, and has killed 69, 000 people annually 
(World Health Organization, [WHO], 2014). Nationally, over 28,000 people died in 2014 from 
drug- poisoning; half of these deaths involved a prescription opioid (Centers for Disease Control 
and Prevention [CDC], 2016). California’s Lake County’s opioid death rates are four times the 
California state average. In 2013, the rate of drug -poisoning deaths in Lake County was 45, 
compared to the State average of 11 (California Department of Public Health, [CDPH], 2016). 
The Controlled Substance Utilization Review and Evaluation System (CURES), California’s 
Prescription Drug Monitoring Program, data illustrates that in 2013, the rate of opioid 
prescriptions was 1767 per 1,000 in the county, over three times the state average of 563. It also 
showed the rate of residents per 1,000 on high doses of over 100 morphine milligram equivalents 
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was 41.1, or five times greater than the state average of 8.1 (State of California Department of 
Justice, 2016). 
In 2014 in Lake County, 23 deaths were attributed solely to drugs (48 deaths from both 
alcohol and drugs), and 52 non-fatal hospitalizations, and 50 non-fatal emergency department 
visits involved opioids (CDPH, 2016). Lake County ranks 50th of 57 in health behaviors, and 
56th of 57 in overall county health outcomes (Robert Wood Johnson Foundation, 2016).  
According to the Morbidity and Mortality Weekly Report (CDC, 2013), in 2010 a total of 
40,393 drug-induced deaths occurred in the United States, 74.3 percent of which were 
unintentional. Prescription drugs have now surpassed illicit drugs as a leading cause of drug-
related overdose deaths (CDC, 2013). 
The nature of the project derives from the ability of intranasal naloxone to reverse opioid 
overdose. Opioid overdose, whether from prescribed or illicit use, can result in respiratory 
depression and death. Naloxone possesses a stronger affinity and ability to bind to opioid 
receptors to temporarily block the effects of opioids and primarily support respiratory status. The 
CNL student can be instrumental in developing and distributing educational materials about the 
administration of intranasal naloxone to assist healthcare providers in informing patients, their 
peers, families, and members of their social network who might witness an overdose. 
Project Overview 
The goals and objectives of the CNL project are to provide education to healthcare 
providers and their supportive staff on the administration of intranasal naloxone. This entails 
research, participation and collaboration in various stakeholder and action team meetings, 
development of a county substance use disorder treatment and support services resource guide, 
the provision of a power-point presentation, demonstration of intranasal administration, and 
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educational materials to interested providers. The aim statement is to reduce the number of fatal 
opioid overdoses by 75 percent in Lake county within 12 months by providing education for 
local healthcare providers on intranasal naloxone administration for opioid users or their family, 
friends, peers, or members of their social network. This relates to the global aim goal. The CNL 
aims to improve access and education to intranasal naloxone administration for opioid users or 
their family, friends, peers, or members of their social network through education provided to 
healthcare providers or their support staff in clinics in our county.  
 The actual workflow process begins with providing access (prescription) to intranasal 
naloxone and educating opioid users and their family, friends, peers, or members of their social 
network about its administration. The process ends with the opioid user or their friends, family, 
peers, or members of their social network obtaining intranasal naloxone and the knowledge for 
its administration, and potentially utilizing it and saving a life. By working on the process, the 
CNL student expected to improve patient outcomes, improve patient safety, and improve the 
quality of care. It was important to work on this because the CNL student had identified the need 
to improve patient outcomes, improve patient safety, and improve the quality of care. Access to 
intranasal naloxone and education in its use provided to opioid users and their family, friends, 
peers, or social network can help reverse an opioid overdose, and potentially prevent death.  
Rationale 
The project originated from a countywide initiative raising the awareness of high rates of 
opioid misuse and opioid deaths in the County of Lake. The county initiative is known as Safe 
Rx Lake County (2016), and has been formed through collaboration with Partnership HealthPlan 
of California (2016) and the California Health Care Foundation (2016). The CNL student, and 
preceptor, Dr. Karen Tait, Lake County Health Officer, mutually identified a suitable project that 
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could have beneficial impact in the community. As a public health nurse working in the Lake 
County health department, it was a complementary opportunity to positively influence 
community health outcomes.  
This was an evidence-based project with a multitude of literature on the topic of 
prescription and non-prescription opioid misuse, and naloxone. Intramuscular naloxone, as well 
as its intranasal formulation, has successfully been used in many harm-reduction programs, 
substance abuse programs, and pre-hospital Emergency Medical Services (EMS) for the reversal 
of opioid overdose.  
Opioid misuse, including prescription opioids, has reached epidemic proportions (CDC, 
2016). Naloxone, an opioid reversal agent, can reverse the effects of an opioid overdose of 
prescription opioids, as well as non-prescription opioids, such as heroin. Through awareness 
campaigns and prescription practice guideline changes, intranasal naloxone is now available to 
patients, their family members, peers, or members of their social network even without a 
prescription through participating pharmacies. The importance of knowledge of its 
administration is life-saving. 
The opioid epidemic is now well recognized throughout the United States. Recent 
attention has focused on the celebrity Prince, who reportedly died from an overdose of a 
powerful opioid (Associated Press, 2016). Prince, reportedly struggling with pain issues, had 
been prescribed an opioid, which resulted in an accidental overdose and death. According to Dr. 
Barbarajean Magnani, pathologist-in-chief at Tufts Medical Center, "celebrities bring it to our 
attention, but we see this every day” (Associated Press, 2016, p. 1).  
The data is astounding. According to the CDC (2016), seventy-eight Americans die each 
day from an opioid overdose. The rate of overdose deaths involving opioids quadrupled since 
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1999. In 2014, over two million Americans were abusing or dependent upon prescription 
opioids, and there were more deaths attributed to opioid overdose than ever. From 2000 to 2014, 
nearly half a million people died from drug overdoses; the majority of deaths (more than six out 
of ten) involved an opioid.  
The CNL student’s local county is no exception. The county’s death rates are four times 
higher than the State average (California Department of Public Health, 2016). Collectively, the 
California Healthcare Foundation, Partnership HealthPlan of California, and the local county 
have developed a coalition to mitigate this serious issue. There are many interventions ranging 
from new prescribing guidelines (thus significantly reduced prescriptions), increased therapeutic 
treatment programs, and the Controlled Substance Utilization Review and Evaluation System 
(CURES), or the California Drug Monitoring Program (State of California Department of 
Justice, 2016). CURES is a database that displays patient prescription history, prescribing 
physicians, dispensing information, and refill intervals, and is accessible to both clinicians and 
pharmacists for monitoring, safe prescribing, and drug diversion prevention. In addition to these 
aggressive measures, a reversal agent, naloxone, has been proven to be effective against opioid 
overdose (Mueller, Walley, Calcaterra, Glanz, and Binswanger, 2015). 
The CNL student can be effective in assisting to broaden the education and use of the 
reversal agent within the constraints of a collaborative pilot program. Since this is a novel 
initiative in the county, healthcare providers may not have been educated on this topic. In 
addition, the mainstreaming of naloxone prescription may soften the stigma associated with harm 
reduction programs, such as needle exchange programs. The CNL student also assisted in the 
development of a resource guide of available substance abuse treatment and support options for 
dissemination in the county. 
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The aim statement was to reduce the number of fatal opioid overdoses in the county by 
75 percent within 12 months by providing education on intranasal naloxone administration to 
healthcare providers for opioid users or their family, friends, peers, or members of their social 
network. The identified threats included lack of control over prescribing and education 
administration, availability of venues, provider or healthcare organization disinterest, timelines, 
and political conservatism that may have hindered widespread dissemination of substance abuse 
and naloxone awareness. To mitigate these potential unintentional threats, the CNL student 
pursued additional opportunities to provide educational materials through newly available 
venues. For instance, the Lake County Office of Alcohol and Other Drug Services (AODS) 
received $30,000 of grant funds for 200 Narcan Nasal Spray kits. The CNL student had planned 
to provide education in this endeavor, as well. In addition, the CNL student recorded a webinar 
on intranasal naloxone administration through California Partnership HealthPlan for potential 
future use for other providers. The project strove to improve patient outcomes, improve patient 
safety, and improve the quality of care.  
Opioid overdoses claim 78 Americans’ lives daily in the United States (CDC, 2016). 
Since naloxone has the ability to reverse overdose, the potential for lives saved is thus very high. 
The cost of implementing the CNL student project of naloxone education was estimated to be  
$ 7,900. This encompassed the average salary of a local public health nurse ($35.00 an hour) at 
220 total hours, including the cost of computer use, copies, patient education materials, 
transportation, and utility services such as phone, Internet, and electricity estimated at an 
additional $200. However, since providers were not charged during this academic project, this 
cost may be viewed as a savings to provider organizations. Naloxone itself is prescribed, and is 
not funded by the providers, but by Medi-cal. The mucosal atomization device used in 
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conjunction with the prescribed naloxone has been supplied free of charge by Partnership 
HealthPlan of California.  
A literature review published in Population Health Management found that those who 
misuse opioids generally also use more healthcare services, such as the emergency department, 
outpatient physician services, and inpatient hospital admissions (Meyer, Patel, Rattana, Quock, 
and Mody, 2014). The same review identified that the mean annual excess utilization healthcare 
costs for opioid misusers with private insurance ranged from $14,054 to $20,546, and those with 
Medicaid from $5874 to $15,183. A study published in the Journal of the American Medical 
Association identified 135, 971 emergency department visits nationally for opioid overdose in 
2010, and inpatient and emergency room expenses totaling $2.3 billion (Yokell, Delgado, Zaller, 
Wang, McGowan, and Green, 2014). Naloxone distribution was found cost-effective and cost 
saving, resulting in fewer overdoses and usages of the emergency medical service system 
(Cofflin and Sullivan, 2013). Cofflin et al. (2016) demonstrated that emergency department visits 
were reduced with co-prescription of naloxone.  
The cost savings of lives, of course, is difficult to quantitatively assess. In this case, cost 
utility analysis is utilized, and the value and the quality of life are expressed in quality adjusted 
life years (Penner, 2013). In a meta-analysis by Cofflin and Sullivan (2013), six percent of 
overdose deaths were prevented with naloxone distribution; one death was prevented for every 
227 naloxone kits distributed. Naloxone distribution increased costs by $53, while increasing 
quality-adjusted life-years by 0.119 for an incremental cost-effectiveness ratio of $438, or cost 
per quality-adjusted life year (QALY) gained. According to Meyer, Patel, Rattana, Quock, and 
Mody (2014), the societal burden of opioid overdose results in 830,652 years of potential life lost 
before age 65. 




The PICO question posed was: Does naloxone reduce the number of deaths from opioid 
overdose in the community? The initial search in the University of San Francisco Gleeson 
Library Cumulative Index to Nursing and Allied Health Literature (CINAHL) database revealed 
66 results of peer-reviewed articles between 2009-2016 when using the words naloxone and 
community. When using the words naloxone, community, and death, the results tightened to 15, 
the majority of which were pertinent.   
Mueller, Walley, Calcaterra, Glanz, and Binswanger (2015) summarized and classified 
publications on overdose education and naloxone distribution to assess effectiveness, and 
concluded that naloxone hydrochloride is the standard of care for treatment of opioid induced 
respiratory depression. It is standard practice in emergency settings for patients with an opioid-
induced coma or respiratory depression because of its rapid action as an opioid–receptor 
antagonist (Compton, Volkow, Throckmorton, and Lurie, 2013). Naloxone has been used for 
over 40 years in the hospital setting, emergency departments, and pre-hospital Emergency 
Medical Services (EMS). It has also been used for years in harm reduction programs, such as 
those lead by the San Francisco Department of Public Health (2016). The evidence for the 
effectiveness of intramuscular naloxone, and its intranasal form, is abundant. In a prospective, 
nonrandomized trial of the administration of intranasal naloxone by paramedics to patients with 
suspected opiate overdoses over a six-month period, intranasal naloxone was shown to have an 
83 % effectiveness rate, with potential results projected to be higher in actual practice (Barton et 
al., 2005). The intranasal route possesses benefits of rapid onset, high plasma bioavailability, 
direct passage to the central nervous system via the olfactory mucosa bypassing first pass 
metabolism, and the elimination of needles (Barton et al, 2005). A 2009 randomized control trial 
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study concluded that intranasal naloxone reversed opioid overdose successfully in 82% of 
patients, and the intranasal route was as effective as the then more frequently used intramuscular 
route as a first-line treatment for opioid overdose. Additional benefits of the intranasal route are 
ease of access and administration and increased safety from reduced exposure risk to blood-
borne pathogens such as hepatitis B, hepatitis C, and human-immunodeficiency virus from 
accidental needle- stick injuries (Kerr, Kelly, Dietze, Jolley, and Barger, 2009). Robinson and 
Wermeling (2014) concluded that intranasal naloxone is as effective as intravenous 
administration at reversing the central nervous system-depressing effects of opioids, by 
comparing respiratory rates and Glascow Coma Scale values before and after naloxone 
administration. 
Opioids have binding sites in the brain, nervous system, and limbic system known as 
opioid receptors. There are essentially three types of opioid receptors: mu, delta, and kappa. Mu-
receptors are responsible for opioid-induced euphoria, analgesia, sedation, and respiratory 
depression (Adams, Holland, and Urban, 2015). By depressing the respiratory drive, resultant 
hypoxemia leads to cerebral hypoxia, impaired consciousness, respiratory arrest, cardiac 
dysthymias, and cardiac arrest (WHO, 2014). Enteen et al. (2010) corroborate that death is due to 
cardiac arrest following hypoxia from the opioid suppression of the central respiratory drive. 
Naloxone, an opioid antagonist, possesses has a higher affinity for mu-receptors, and virtually 
competes with and defeats opioids to bind the mu-receptors. Naloxone replaces the opioid 
agonist and reverses the biological effects that are caused by opioids, such as respiratory 
depression, and consequent fatal opioid overdose. Intranasal naloxone’s onset is three to five 
minutes, and its duration of action ranges from 30- 90 minutes (WHO, 2014). 
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In 2006, the Boston Public Health Commission started an overdose prevention program 
and distributed intranasal naloxone kits to community members. After training 385 individuals, 
74 successful naloxone overdoes reversals were reported, and intranasal naloxone administration 
was deemed as effective as intravenous administration (Robinson and Wermeling, 2014).  
The incidence of fatal opioid overdose among opioid-dependent individuals is estimated 
at 0.65 per 100 person years, and non-fatal opioid overdoses are several times more common 
(WHO, 2014). The estimated mortality rate in overdoses where naloxone was administered by 
witnesses is one percent, while the estimated mortality rate of opioid overdose where community 
use of naloxone was not available is two to four percent (WHO, 2014). 
Naloxone exhibits no pharmacological effect on an opioid-naïve person, is not a 
controlled substance, and does not have addictive potential (Harm Reduction Coalition, 2012; 
Straus, 2013). Naloxone has relatively mild side effects, as those of opioid withdrawal, and while 
unpleasant, are not life-threatening (Kerr, 2009). The most common side effects are nausea and 
vomiting, while seizures were reported in 0.45% of overdose reversals (WHO, 2014).  
In post-operative reversal of central nervous system and respiratory depression, life- 
threatening adverse effects such as ventricular arrhythmias, ventricular fibrillation, hypertension, 
hypotension, tachycardia, pulmonary edema, encephalopathy, coma, and death have been 
reported (DrugInserts.com, 2013). This is attributed to rapid or larger doses than those used in 
the community, and potentially underlying cardiovascular conditions, or use of cardiotoxic 
medications. It is to be used in caution with pregnant women, as it can cause withdrawal of the 
fetus and mother, and is to be avoided in neonates due to potential abstinence withdrawal 
syndrome (DrugInserts.com, 2016).  
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Organizations such as the American Society of Anesthesiologists (2014), the American 
Medical Association (2016), the Office of National Drug Control Policy (2016), the Substance 
Abuse and Mental Health Services Administration (2016), Project Prescribe to Prevent (2016), 
and many others support the use of intranasal naloxone by laypersons in successful opioid 
overdose reversal. This position statement from the American Society of Addiction Medicine 
(2014) supports comprehensive training for naloxone administration, increased use of naloxone 
in opioid overdose, and expanded accessibility to naloxone for those who are likely to witness 
opioid overdose. In their systemic review of naloxone distribution programs, Clark, Wilder, & 
Winstanle (2014) concluded that bystanders will successfully use naloxone to reverse opioid 
overdoses when properly trained through these programs. A systematic review of studies on 
take-home naloxone to reverse opioid overdose included 21 studies for analysis. One interrupted 
time-series study, involving 2, 912 opioid users at risk of overdose in 19 communities followed 
for seven years, demonstrated that education and training intervention complemented by take-
home naloxone decreased overdose-related mortality (European Monitoring Centre for Drugs 
and Drug Addiction, 2015).  
A systematic review and descriptive meta-analysis of the international Take-Home 
Naloxone programs literature study estimates that nine percent of naloxone kits distributed are 
likely to be used by peers within the first three months for every 100 trained (McAuley, Aucott, 
and Matheson, 2015). Lim, Bratberg, Davis, Green, and Walley (2016) provide an educational 
tool that instructs prescribers and pharmacists on the administration of naloxone, in accordance 
with the priority recommendation of the United States Department of Health and Human 
Services of expanded use and distribution of naloxone for reducing opioid overdose. The meta-
analysis by Giglio, Li, and DiMaggio (2015) demonstrated that bystander naloxone 
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administration and overdose education programs are associated with increased odds of recovery 
from overdose. 
Since 1996, overdose education and naloxone distribution programs have been 
successfully distributing naloxone kits and training in their use to laypersons. An evaluation of a 
program in Massachusetts that trained over 2,900 potential overdose bystanders, reported that 
opioid overdose death rates were significantly reduced in communities in which the program was 
implemented as compared to those in which it was not (Walley et al, 2013). 
In 2006, the Chicago Recovery Alliance distributed 3,500 intramuscular naloxone doses 
to opioid users, with 319 reported peer reversals. A twenty percent reduction in opioid deaths, 
with a ten percent additional reduction for the second and third years, were reported by the Cook 
County medical examiner (Wermeling, 2010). By August 2011, 22,010 overdose prevention 
encounters and 2,720 peer opiate-related overdose reversals had been reported (Harm Reduction, 
2012).  
The San Francisco Drug Overdose Prevention and Education (DOPE) Project has a long-
standing history of naloxone distribution and success. The DOPE Project, the first naloxone 
prescription program established in conjunction with a county health department, the San 
Francisco Department of Public Health, reported that from 2003 to 2009, 1,942 individuals were 
trained and prescribed naloxone, 399 naloxone doses were administered, and 89 % opioid 
overdoses were reversed (Enteen et al., 2010). 
 The Baltimore Student Harm Reduction Coalition is Maryland ’s first community-based, 
state-authorized training program for third-party naloxone prescription. During an eight-month 
pilot period, 250 free naloxone kits were distributed, and three overdose reversals were reported. 
Trainings were also found effective in increasing self-efficacy in overdose prevention and 
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response, persisting up to 12 months (Lewis et al., 2016). Bennett & Holloway’s (2012) 
evaluation of the Take- Home- Naloxone- Project in Wales determined that knowledge, 
confidence, ability, willingness, and successful administration of naloxone improved with 
education and training, and of 28 administrations of naloxone, 27 overdose reversals were 
reported.  
 A review of six overdose education and naloxone distribution programs concluded that 
trained participants were more likely to recognize overdose, and identify when naloxone 
administration was indicated, compared with those who had not received training (Cofflin and 
Sullivan, 2013). Chicago, New York, San Francisco, Baltimore, and New Mexico boast 
successful naloxone distribution and training programs through their overdose prevention 
programs (Doe-Simkins, Walley, Epstein, and Moyer, 2009). 
One of the major goals of the American Medical Association Task Force is to encourage 
physicians to co-prescribe naloxone to a patient, or prescribe naloxone to a family member or 
peer when clinically appropriate. These prescriptions are favored, especially if the patient is on a 
high opioid dose, has concomitant benzodiazepine prescription, history of substance use 
disorder, [and possibly Suboxone or Methadone therapy], has an underlying mental health or 
comorbid medical condition, or might likely assist someone who overdoses (American Medical 
Association, 2016). 
Traditionally, legal concerns may have discouraged providers to participate in overdose 
education and naloxone prescribing. Some of the issues of expanding overdose education and 
naloxone prescription programs in the community include medical providers’ reluctance to 
prescribe naloxone. Medical providers may be concerned about legal ramifications, bystanders’ 
ability to accurately recognize an overdose and administer naloxone, or promoting riskier drug 
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behavior. In a legal review of naloxone prescribing, medical providers who prescribe naloxone 
consistent with state and federal laws drug prescribing laws realize a low risk for malpractice 
(Beletsky, 2012). Naloxone can be prescribed by any licensed heathcare provider. However, 
there are additional laws that offer greater protection and support. California Assembly Bill 
AB635 (2014) encourages providers to prescribe to those with chronic opioid use, third- party 
prescribing, standing orders for dispensing by community workers, and layperson possession and 
administration of naloxone (California Legislative Information, 2014). Pharmacists, too, can 
prescribe and dispense naloxone, by virtue of California Assembly Bill AB1535 (2015) after 
undergoing brief training (California Legislative Information, 2015). There is, however, current 
reluctance in the county on the part of the pharmacists, to do so without a prescription from the 
physician.  
Some individuals with criminal justice involvement or illicit drug use may hesitate to 
render aid and call 911, out of fear of prosecution (Cofflin & Sullivan, 2013). Good Samaritan 
Laws, California Assembly Bill AB472 (2012), protect citizens who administer naloxone and 
seek medical help from civil and criminal liabilities for minor drug and alcohol violations. These 
laws further support the success of naloxone programs (California Legislative Information, 
2012). 
Methodology 
A fishbone, or cause and effect, diagram was created to illustrate the multifactorial nature    
of fatal opioid overdose in Lake County. Refer to Appendix A for the cause- and -effect diagram. 
An analysis was also performed to identify strengths, weaknesses, opportunities, and threats 
(SWOT) to the CNL student project. Refer to Appendix B for the SWOT analysis. The 
theoretical framework used in the CNL project was the Institute of Healthcare Improvement’s 
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(IHI) Model for Improvement, which focuses on aims, measures, and appropriate changes 
(Institute for Healthcare Improvement, 2016). The actions taken to implement the project mirror 
those of the IHI’s Plan-Do-Study-Act (PDSA) cycles (IHI, 2016). The planning stage involved 
numerous meetings with stakeholders, multiple agencies, and Partnership HealthPlan of 
California, and vast research. The implementation segment of the PDSA cycle involved the 
arrangement of trainings with providers interested in prescribing intranasal naloxone to patients, 
and interested in receiving the training for clinical and supportive staff. This entailed 
collaborating with multiple health organizations across multiple administrative strata, such as the 
local county Alcohol and Other Drugs Services, Adventist Health, Sutter Health, Mendocino 
Community Health, Lake County Tribal Health Consortium, and local private clinics, such as 
Lucerne Community Clinic.  
The initial phase was implemented at Lucerne Community Clinic. The second phase was 
implemented at three clinic sites in Lakeport, Ukiah, and Willits, California within the 
Mendocino Community Health Clinic network. During the second phase, the CNL student also 
recorded an intranasal naloxone education webinar for Partnership HealthPlan of California, 
which has been posted on their Managing Pain Safely website. The third phase was implemented 
at the Lake County Tribal Health Consortium and the Lake County Public Health Department, 
and a treatment and support resource directory was developed. Refer to Appendix C for a 
diagram of the PDSA cycles. 
The specific actions entailed the provision of training, demonstration, and patient 
education material for providers and their staff for educating their clients, families, peers, and 
members of their social network on the administration of naloxone. During meetings at the clinic 
or provider office, the CNL student provided a power-point presentation of intranasal naloxone 
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to providers and their supportive staff, demonstrated assembly and simulated administration, and 
provided educational materials to be used by providers and patients and their families and peers. 
The study phase of the PDSA consisted of reviewing the questions and comments posed by the 
audience or noted problems, and adjusting future presentations in the next PDSA cycle. The 
culminating study phase consisted of evaluating the outcome results. 
The goal of the project was to create educational material for the administration of 
intranasal naloxone for healthcare providers to provide to their patients who are prescribed or 
suspected of illicit use of opioids, or to their families, friends, peer, or members of their social 
network. Initially, the CNL student concentrated on providing a power-point presentation, 
intranasal naloxone administration demonstration and educational materials to a local community 
clinic, as part of a pilot project lead by Partnership HealthPlan of California. Although the 
number of actual prescriptions at the community clinic within the first month was low, 
presumably due to effective opioid dose control and Suboxone treatment, the risk for overdose 
for this population remained high. As the initiative advanced, the need for additional clinics and 
providers to provide intranasal naloxone ensued, and the parameters of the project expanded. 
A state grant for another formulation of intranasal naloxone, Narcan Nasal Spray, from a 
different manufacturer, Adapt Pharma, had been approved. The medication had been delivered 
and the CNL student met with the AODS coordinator to assist in providing educational materials 
and demonstration for this product. This particular product is accompanied by pre-tooled 
educational videos and provider information. However, it was determined that AODS required 
greater infrastructure to legally dispense naloxone in the community, such as a standing order 
and recognition as an overdose education and naloxone distribution program. The CNL student 
planned to meet with AODS, Partnership HealthPlan, and the Safe Rx Lake County Coalition on 
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August 15, 2016 to plan future actions. The CNL student planned to continue the PDSA cycles 
with other clinics, and the community. 
Timeline 
The timeline of the implementation of the CNL student project can be viewed in 
Appendix E. The implementation began with vast research, collaboration with Partnership 
HealthPlan of California, and preparation and development of an educational power-point 
presentation and demonstration of intranasal naloxone. International Medication Systems, Ltd., 
was contacted to obtain naloxone demonstration kits. The presentation was then delivered, along 
with a demonstration of intranasal naloxone administration and educational materials, at the 
Lucerne Community Clinic in April 2016. Continued research and efforts to spread the 
improvement project continued through May and June 2016, as well as attendance of 
collaborative meetings within various facets of the county initiative. The CNL student met with 
the Safe Rx Lake County Treatment and Support Resource Action Team, and assisted in 
developing a resource guide for substance abuse treatment and support services. During this 
period, the CNL student also attended the Safe Rx Lake County Provider and Law Enforcement 
Action Team meeting in which new county practice guidelines were reviewed, along with a 
discussion of intranasal naloxone dissemination and education. During June, various clinics were 
contacted to assess their interest in prescribing intranasal naloxone through Partnership 
HealthPlan of California with subsequent education, with efforts continued in July. The CNL 
student also recorded a webinar on intranasal naloxone administration with Partnership 
HealthPlan of California, which was posted on their website, Managing Pain Safely (Partnership 
HealthPlan of California, 2016). In July, the CNL student delivered the education to an 
additional three interested clinics from Mendocino Community Health Clinics in Lakeport, 
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Ukiah, and Willits, California. During July, the CNL student met with the Lake County Alcohol 
and Other Drugs Services (AODS) Substance Abuse Coordinator to discuss dissemination tactics 
for the Narcan Nasal Spray from Adapt Pharma acquired through a state grant. Two hundred 
complete kits valued at $30, 000 could be disseminated in the community. However, upon 
review, additional infrastructure measures, such as a standing order and registration as an opioid 
education and naloxone distribution program, were warranted. A follow-up meeting with 
Partnership HealthPlan of California, the Safe Rx Lake County Coalition, AODS, and the CNL 
student will ensue on August 15, 2016 to explore these issues. Another educational opportunity 
arose to provide the education to Lake County Tribal Health Consortium, and to the public health 
nurses at Lake County Public Health Department on August 3, 2016.  
Expected Results 
To evaluate the effectiveness of the project, the collected data focused on the number of 
fatal drug overdoses, extracted from statistics from the California Department of Public Health, 
although this generally lags by several years. Other relevant data included the number of opioid-
related emergency department visits, and the number of opioid–related hospitalizations, which is 
also delayed. A real-time measure is the number of naloxone prescriptions and recipient trainings 
dispensed, which was requested of participating agencies. An important evaluation measure is 
the county coroner reports of death due to opioid overdose. Upon review of the county coroner 
death reports from January 2016 to August 2016, two of the six drug-related deaths were 
affiliated with opioids (Lake County Sheriff’s Department, 2016). According to Dr. Karen Tait, 
Lake County Health Officer, 26 drug-related deaths were attributed to opioids in 2015 (K. Tait, 
personal communication, August 1, 2016). The ideal of reaching the desired 100 % reduction in 
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fatal opioid overdose is naturally desired, but one saved life is worth the project effort. A goal of 
25 % reduction in opioid overdoses would be anticipated in the first six months, followed by  
50 % in nine months, and 75 % in 12 months, or April 2017. This would compute to a total of  
20 deaths at six months, 13 deaths at nine months, and six deaths at 12 months, or a reduction of 
six deaths at six months, 13 deaths at nine months, and 20 deaths at 12 months.  
Overall increased awareness of the tragic risks of opioid overdose, substance use 
disorders, and harm reduction were also expected achievements. In the 2015 Memorandum to 
Federal Departments and Agencies, President Obama aimed to double the number of providers 
that prescribe naloxone (The White House, 2015). With international, national, state, local, and 
Clinical Nurse Leader efforts, overall rates of fatal opioid overdose are expected to fall, but it 
will take some time to realize the results. 
Nursing Relevance 
The relevance to nursing is the value of improving patient outcomes through system 
analysis, risk anticipation, health outcomes management, and education. The CNL can raise 
awareness of substance use disorders, treatment and support resources, and the need for 
anticipated measures to reverse opioid overdose and prevent unnecessary patient death. Through 
the CNL competencies, the CNL can help the local and broader global community in reducing 
the number of deaths due to opioid misuse. The project demonstrated that nurses can lead in their 
communities and positively impact the health of populations.  
“Despite its potential to safely, rapidly, and completely reverse an opioid overdose, the 
public health impact of this medication has not yet reached its full potential” (Compton, Volkow, 
Throckmorton, and Lurie, 2013, p. 65). In its resolution, the American Medical Association 
supports the use of nasal naloxone by trained non-medical personnel, advocates for routine 
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education of all patients receiving prescription opioids, those at risk, and their families and peers, 
and advocates for the routine prescription of nasal naloxone to all patients at risk (Drug Policy 
Alliance, 2016). The Centers for Disease Control and Prevention (2016) advocates for public 
health departments implementing community-based opioid drug overdose prevention programs, 
including training, and naloxone provision to potential overdose witnesses to mitigate the opioid 
crisis (CDC, 2012). According to Doe-Simkins, Walley, Epstein, and Moyer (2009), overdose 
prevention programs that include the distribution of intranasal naloxone by nonmedical 
personnel are feasible public health interventions for city public health departments 
The monumental passage of Senate Bill SB 524, the Comprehensive Addiction and 
Recovery Act of 2016 calls for robust efforts to mitigate the opioid issue, including greater access 
to naloxone, approving $181 million in funding for states to combat opioid addiction through 
multiple efforts. States will no longer be dependent on their budgets alone to provide basic public 
health education and supplies such as naloxone (Community Anti-Drug Coalitions of America, 
2016). 
As members of the most trusted profession, nurses are in a position to educate patients, 
and influence laypersons and boost their confidence in administering naloxone. Lead researcher 
of the San Francisco Public Health Department, Dr. Phillip Cofflin (2016), stated in the recent 
publication in the Annals of Internal Medicine, patients who legally use opioids in their pain 
management may not realize they are at risk of an overdose. According to the National 
Development and Research Institute (2015), legal opioid users tend to be “wholly misinformed” 
about the dangers of overdose, and are not even aware of the signs of overdose. CNLs can 
provide the necessary education to prevent accidental overdoses to this population. According to 
Dr. Cofflin, "we're prescribing naloxone for risky drugs, not risky patients” (Neergaard, 2016. p. 
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1). Dr. Cofflin commented that trainings also offer an opportunity to provide substance use 
education to minimize stigma and expand the impact of trainings beyond the administration of 
naloxone (Cofflin et al., 2016). 
Reducing disparity and the overall stigma of substance use disorder is also a benefit of 
this CNL student project. Lake County’s population of 65,00 includes 80% White, 17 % 
Hispanic, 3.2 % African American, American Indians 1.1%, and Asian 0.2 % within a 1,300 
square miles radius. The per capita income is $21, 000, and 24.3% live in poverty 
(CityData.com, 2013). Hispanics and American Indian groups have a higher growth rate of non-
medical usage of opioids before the age of 12 as compared to the national rate of 4.2 %; 4.3 % 
and 6.9 %, respectively (Katzman et al., 2016). According to the Indian Health Services, by 
2014, 130 died daily from opioid overdoses in Indian Country (Karol, 2016). By addressing 
disparity with cultural sensitivity, the CNL can also help reach vulnerable populations in the 
community.  
In a recent observational study published in the Annals of Internal Medicine, Cofflin et al. 
(2016) concluded that naloxone can be successfully co-prescribed in the primary care setting, 
and is independently associated with a reduction in opioid-related emergency department visits. 
The study also suggests that training in overdose education opens up dialogue with patients and 
their families, and may have an effect on patient’s substance use behavior. 
     Evaluation 
 
 It is too early to realize the results of the CNL project, and data from reporting agencies 
such as the California Department of Public Health, lags by several years. The number of fatal 
opioid overdoses would be the best metric utilized to evaluate effectiveness. In addition, real -
time data include the number of naloxone prescriptions and related education. Since the project 
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initiation, Lucerne Community Clinic has prescribed eight naloxone prescriptions without a 
reported reversal. Mendocino Community Health Clinic and Lake County Tribal Health 
Consortium have not yet initiated naloxone prescriptions. The estimated number of healthcare 
staff members who received intranasal naloxone education is 100. 
“Achieving high value for patients must become the overarching goal of health care 
delivery, with value defined as the health outcomes achieved per dollar spent. This goal is what 
matters for patients and unites the interests of all actors in the system” (Porter, 2010, p. 2477). 
Improving value benefits all involved parties, the healthcare system, and community. 
The CNL student project adds value to our community as it can potentially reverse opioid 
overdoses, and directly save lives. At the point when an individual has stopped breathing during 
an opioid overdose, he will ultimately die without intervention. With a simple measure such as 
intranasal naloxone, whether or not accompanied by rescue breathing or cardio-pulmonary 
resuscitation, the individual may resume breathing and live. Increased access to naloxone 
potentially reaches people of all age groups, income brackets, ethnicity, education, and includes 
vulnerable populations such as people who use substances, people with HIV, low- income 
persons, older persons, disabled persons, minorities, children and youth, and pregnant women. 
The very essence of public health revolves around improving community and population health, 
and protecting vulnerable populations.  
Unfortunately, the CNL student cannot continue the CNL project, due to the constraints 
of current employment. However, the project is sustainable. The educational materials have been 
created and can further be disseminated via electronic route, and the instructions for 
implementation have been provided. Partnership HealthPlan of California can continue with 
efforts to spread the change. At this point, the change is not ready to be entirely standardized, as 
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additional time to test the changes is needed as naloxone is prescribed in the community. 
However, standardization is anticipated, as naloxone is the standard of care for opioid overdose. 
It is now important to hold the gains made, maintain aims that were identified, and keep 
spreading the change to other sites. The components of sustainability include modification of the 
program after continued spread and analysis, affirmation of a champion (such as Partnership or 
Safe Rx Lake County), alignment with Partnership’s or the Coalition’s organizational mission to 
improve the health of its constituents, and increased perceived benefits of staff and clients 
through experience with the results of naloxone. 
Additionally, support from stakeholders is expected to increase as the project’s relevance 
spreads. The recent legislation to increase the capacity of Suboxone providers from the previous 
ceiling of 100 to 275 patients is promising in the continued mitigation of the opioid problem. The 
Comprehensive Addiction and Recovery Act of 2016 (Community Anti-Drug Coalitions of 
America, 2016), is a monumental legislation that supports grant programs for the expansion of 
prevention, education, treatment, and recovery efforts. One of its many measures that include 
education about naloxone, is expanding its availability to law enforcement agencies and other 
first responders for opioid overdose reversal. Section 202 authorizes the Department of Health 
and Human Services to award grants to state, local, and tribal law enforcement agencies for 
training in the use of naloxone and for the purchase of naloxone. This CNL student project will 
expand and endure for the benefit of the county, and the greater community.  
In 2014, the Harm Reduction Coalition determined that since 1996, it has provided 
naloxone kits to 152,283 laypersons with 26,463 overdose reported reversals. Providing opioid 
overdose training and naloxone kits to individuals in the patient’s sphere can help reduce opioid 
overdose mortality (Wheeler, Jones, Gilbert, & Davidson, 2015).  
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Published material used in this project included educational handouts from the Harm 
Reduction Coalition, Prescribe to Prevent Project, the San Francisco Department of Public 
Health, and Partnership HealthPlan of California. 
Conclusion 
Lake County has already experienced tremendous success through the efforts of 
Annunziata van Voorene, MCSW, ACSW, and Any Positive Change, a local harm reduction 
organization. The organization reports 19 opioid reversals with intramuscular naloxone in 2015 
alone (A. van Voorene, personal communication, July 31, 2016). It is not a matter of whether 
naloxone is effective, but how to increase its acceptance and the integration of the reality of 
substance use disorder and its treatment in Lake County. Through continued efforts of the Safe 
Rx Lake County Coalition, continued successes may break through the current barriers and bring 
realistic solutions to real issues. It has been a tremendously rewarding CNL student project, and 
will hopefully blossom to its true potential. There is nothing more precious than saving a life, 
even through simple measures. “We can do no great things; only small things with great love” -
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